首页> 外文期刊>胸部外科 >Surgical treatment for primary non-small cell lung cancer with synchronous brain metastases
【24h】

Surgical treatment for primary non-small cell lung cancer with synchronous brain metastases

机译:原发性非小细胞肺癌同步性脑转移的外科治疗

获取原文
获取原文并翻译 | 示例
           

摘要

The brain is one of the most common sites of metastasis from lung cancer. The strategies of treatment for non-small cell lung cancer patient with synchronous brain metastases (stage IV) is controversial. We evaluate retrospectively the effectiveness of surgical treatment for these patients. Forty patients were divided into 3 groups on the basis of surgical treatment, group A of patients received both lung and brain resection, group B of patients received lung resection plus gamma knife therapy, group C of patients received brain resection. Median survival from the date of diagnosis of brain metastasis was as follows: group A 331 days, group B 151 days and group C 92 days. Univariate analysis revealed that adenocarcinoma histology and serum LDH significantly affected survival. Multivariate analysis found that only adeocarcinoma histology also affected the survival. It is concluded that surgical treatment may acceptable in selected group of non-small cell lung cancer patients with synchronous brain metastases.
机译:大脑是肺癌最常见的转移部位之一。具有同步性脑转移的非小细胞肺癌患者的治疗策略(IV期)存在争议。我们回顾性评估这些患者的手术治疗效果。 40例患者根据手术治疗分为3组,A组同时接受肺和脑切除,B组接受肺切除加伽玛刀治疗,C组接受脑切除。从脑转移诊断之日起的中位生存期如下:A组331天,B组151天,C组92天。单因素分析显示,腺癌的组织学和血清LDH显着影响生存率。多变量分析发现,仅癌组织学也影响生存。结论是,外科治疗在某些具有同步脑转移的非小细胞肺癌患者中是可以接受的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号